Cardiovascular Effects of ADHD Therapies: JACC Review Topic of the Week
- PMID: 32792083
- DOI: 10.1016/j.jacc.2020.05.081
Cardiovascular Effects of ADHD Therapies: JACC Review Topic of the Week
Abstract
Although the prevalence of attention-deficit/hyperactivity disorder (ADHD) has been stable over the past 3 decades, prescriptions of sympathomimetic stimulants have steadily increased in the United States. This study consisted of a systematic review of PubMed articles screened for ADHD medications and potential cardiovascular toxicity as well as nondrug strategies for managing ADHD. The cumulative body of data showed that ADHD medications cause modest elevations in resting heart rate and blood pressure. Other adverse effects reported with ADHD stimulants included arrhythmia, nonischemic cardiomyopathy, Takotsubo cardiomyopathy, and sudden death. However, such reports did not imply causation, and there was a paucity of randomized trial evidence addressing long-term safety of ADHD medications, particularly among adults. Further studies are essential to clarify the risks and benefits of ADHD stimulant medications and to explore nonpharmacological options, including regular exercise and omega-3 fatty acids, which could be helpful for improving ADHD symptoms.
Keywords: ADHD; amphetamine salts; amphetamines; arrhythmia; atomoxetine; attention-deficit/hyperactivity disorder; cardiomyopathy; cardiotoxicity; exercise; lisdexamfetamine; methylphenidate; omega-3; sudden death.
Copyright © 2020. Published by Elsevier Inc.
Similar articles
-
Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. CNS Drugs. 2013. PMID: 23160939 Review.
-
Recommendation for Long-term Management of Adult Attention-Deficit/Hyperactivity Disorder in Military Populations, Veterans, and Dependents: A Narrative Review.Mil Med. 2024 May 18;189(5-6):e1343-e1352. doi: 10.1093/milmed/usad403. Mil Med. 2024. PMID: 37878798 Review.
-
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.PLoS One. 2020 Oct 21;15(10):e0240584. doi: 10.1371/journal.pone.0240584. eCollection 2020. PLoS One. 2020. PMID: 33085721 Free PMC article.
-
Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30. Ann Pharmacother. 2014. PMID: 24982313 Review.
-
Current pharmacotherapy of attention deficit hyperactivity disorder.Drugs Today (Barc). 2013 Oct;49(10):647-65. doi: 10.1358/dot.2013.49.10.2008996. Drugs Today (Barc). 2013. PMID: 24191257 Review.
Cited by
-
Research progress of tDCS in the treatment of ADHD.J Neural Transm (Vienna). 2024 Nov 7. doi: 10.1007/s00702-024-02853-4. Online ahead of print. J Neural Transm (Vienna). 2024. PMID: 39508850 Review.
-
Serotonergic Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Review of Past Development, Pitfalls and Failures, and a Look to the Future.Psychopharmacol Bull. 2024 Aug 19;54(4):45-80. Psychopharmacol Bull. 2024. PMID: 39263202 Review.
-
Methylphenidate-Induced Non-ischemic Heart Failure With Reduced Ejection Fraction and Mild Pulmonary Hypertension.Cureus. 2024 Mar 5;16(3):e55604. doi: 10.7759/cureus.55604. eCollection 2024 Mar. Cureus. 2024. PMID: 38586757 Free PMC article.
-
Clinical pharmacist intervention to ensure safe stimulant prescribing practices at a Veterans Affairs facility.Ment Health Clin. 2024 Feb 1;14(1):17-22. doi: 10.9740/mhc.2024.02.017. eCollection 2024 Feb. Ment Health Clin. 2024. PMID: 38312441 Free PMC article.
-
Methylphenidate-associated chest pain in a child.BMJ Case Rep. 2023 Nov 27;16(11):e255187. doi: 10.1136/bcr-2023-255187. BMJ Case Rep. 2023. PMID: 38011950
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
